Spike Protein News and Research

RSS

SARS-CoV-2 Omicron variant found to display increased resilience to antiviral type I interferon response

In a new study, scientists have compared the Omicron variant with the Delta VOC (B.1.617.2) as well as the wildtype strain (B.1), with respect to their interaction with the antiviral type 1 interferon response in infected cells.

26 Jan 2022

Effects of the Omicron spike amino acid changes in the interaction with human ACE2 receptor or human antibodies

A recent study analyzed the effects of the interaction between SARS-CoV-2 Omicron spike amino acid and the human ACE2 receptor or with human antibodies.

26 Jan 2022

Anti-SARS-CoV-2 antibodies found in wild mustelids in France

A new study focused on the identification of SARS-CoV-2 infection in wild mustelids in the French region of Brittany.

26 Jan 2022

Cannabidiol inhibits SARS-CoV-2 replication in human cells and mice

In research recently published in the journal of Science Advances, an interdisciplinary team of researchers from the University of Chicago assessed the potential role of cannabidiol (CBD), a natural product extracted from the cannabis plant, to prevent and inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in human cells and mice.

26 Jan 2022

SARS-CoV-2 infection and vaccination-induced T cells cross-recognize Omicron

In a recent study posted to the Nature In Review* preprint server, researchers performed a comprehensive, in-depth comparison of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell epitope repertoire following natural infection of coronavirus disease 2019 (COVID-19) compared to messenger ribonucleic acid (mRNA) vaccinations.

25 Jan 2022

Serum biomarkers for SARS-CoV-2 reinfection identified in rhesus macaques

Many experts now predict that COVID-19, which so far has killed more than 5.5 million people worldwide, will remain endemic as new, infectious variants of SARS-CoV-2 emerge.

25 Jan 2022

Spike-mediated CFTR inhibition accounts for airway inflammation in COVID-19

A new study looks at the molecular level inhibition of the protective CFTR gene by the SARS-CoV-2 spike protein.

25 Jan 2022

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Scientists have recently used synthetic biology to design primary human CD8 T cells to express Spike protein-specific chimeric antigen receptors (ACE2 CAR or anti-Spike CAR).

25 Jan 2022

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

A new study has focused on the identification, in vitro binding, and potent neutralizing activity of STI-9167 (plutavimab) against live viruses and pseudotype viruses.

25 Jan 2022

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

A new study investigated SARS-CoV-2 spike protein responses targeted by cross-reactive T cells that were isolated from convalescent COVID-19 individuals along with previously uninfected donors.

25 Jan 2022

Scientists develop a model to rapidly identify vaccine breakthrough SARS-CoV-2 variants

In a new study, scientists have recently developed a computational model to predict the antigenicity and immune escape ability of emerging variants of SARS-CoV-2.

25 Jan 2022

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

A recent study evaluated the sensitivity and specificity of a “spit and mail” serology test.

25 Jan 2022

LA County study finds COVID-19 'herd immunity' unlikely

In a research letter published in the Journal of the American Medical Association (JAMA), researchers carried out a seroprevalence and vaccination coverage study in Los Angeles County (LAC).

24 Jan 2022

New, low-cost COVID-19 test could make high-performance testing more accessible

Researchers at the University of Washington have developed a new test for COVID-19 that combines the speed of over-the-counter antigen tests with the accuracy of PCR tests that are processed in medical labs and hospitals.

24 Jan 2022

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.

24 Jan 2022

Study finds stable T-Cell response against Omicron after mRNA booster vaccination

A new study measured T cell activity in vaccinated individuals and found a third vaccine provided substantial T-cell immunity against the Omicron variant of SARS-CoV-2.

24 Jan 2022

Researchers are in the race to beat Omicron

David Veesler and his lab members aren't getting much sleep these days. In the final weeks of 2021, he and his team worked around the clock to post four coronavirus papers on the preprint server bioRxiv.

24 Jan 2022

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

A recent study published in the journal Science brings a detailed chemical and molecular perspective on the improved evasion of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the retention of strong interactions with the receptor as two principal factors underneath the notorious transmissibility of the SARS-CoV-2 Omicron variant.

23 Jan 2022

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United States Food and Drug Administration (FDA) for their in vitro potency against several SARS-CoV-2 variants, including the currently dominant Omicron train.

23 Jan 2022

Novel SARS-CoV-2 mutations reported in chronic HIV patients

A new study describes the emergence of new SARS-CoV-2 variants in three immunocompromised patients.

23 Jan 2022

Spike Protein News and Research

SARS-CoV-2 Omicron variant found to display increased resilience to antiviral type I interferon response

Effects of the Omicron spike amino acid changes in the interaction with human ACE2 receptor or human antibodies

Anti-SARS-CoV-2 antibodies found in wild mustelids in France

Cannabidiol inhibits SARS-CoV-2 replication in human cells and mice

SARS-CoV-2 infection and vaccination-induced T cells cross-recognize Omicron

Serum biomarkers for SARS-CoV-2 reinfection identified in rhesus macaques

Spike-mediated CFTR inhibition accounts for airway inflammation in COVID-19

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

Scientists develop a model to rapidly identify vaccine breakthrough SARS-CoV-2 variants

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

LA County study finds COVID-19 'herd immunity' unlikely

New, low-cost COVID-19 test could make high-performance testing more accessible

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Study finds stable T-Cell response against Omicron after mRNA booster vaccination

Researchers are in the race to beat Omicron

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

Novel SARS-CoV-2 mutations reported in chronic HIV patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News